AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2015
Jan 6, 2015
31580_dirs_2015-01-06_52fce9b2-b1ae-4c2d-bad1-b9eb0ccb4146.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2015-01-02
Reporting Person: Schenkein David P (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-02 | Common stock | S | 6500 | $110.08 | Disposed | 229772 | Indirect |
| 2015-01-02 | Common stock | S | 6500 | $110.08 | Disposed | 111772 | Indirect |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $106.76 to $114.39. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F4: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.